NDC 50242-0243-06: Mosunetuzumab 60 mg/.001L Liquid, 6 L Bag
This is a package of 6 l of Mosunetuzumab 60 mg/.001L Liquid from Genentech, Inc., first listed with the FDA Mar 2022 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 50242-243-06 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 50242 labeler · 243 product · 06 package
- Package marketed since
- Mar 2, 2022
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 5024224306 3
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
This is a liquid pharmaceutical product containing mosunetuzumab, a monoclonal antibody typically used in cancer treatment. Mosunetuzumab functions as a bispecific antibody that is commonly used in therapies targeting certain blood cancers by engaging immune cells to attack cancer cells. This listing indicates the product is classified for further processing, meaning it is supplied in a form intended for additional preparation or compounding before clinical use.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 50242-0243-06 You're viewing this Main listing | 6 L in 1 BAG | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Mosunetuzumab 60 mg/.001Lthis 50242-0243-06 | Genentech, | 6 l | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Genentech, Inc. labeler code 50242
- EVRYSDI Risdiplam 5 mg Tablet NDC 50242-202-01
- Gavreto Pralsetinib 100 mg Capsule NDC 50242-210-12
- Xolair PFS omalizumab 75 mg/.5mL Injection, Solution NDC 50242-214-01
- Xolair PFS omalizumab 150 mg/mL Injection, Solution NDC 50242-215-01
- Xolair omalizumab 300 mg/2mL Injection, Solution NDC 50242-227-01
- Mosunetuzumab 10 mg/.001L Liquid NDC 50242-242-01
- Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf 1200 mg/15mL; 600 mg/15mL; 30000 U/15mL Injection, Solution NDC 50242-245-01
- Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf 600 mg/10mL; 600 mg/10mL; 20000 U/10mL Injection, Solution NDC 50242-260-01
- Astegolimab 140 mg/.001L Liquid NDC 50242-400-01
- Omalizumab 150 mg/.001L Liquid NDC 50242-408-01
- Polatuzumab vedotin 50 mg/.001L Liquid NDC 50242-430-01
- Ocrevus Zunovo ocrelizumab and hyaluronidase 23000 U/23mL; 920 mg/23mL Injection, Solution NDC 50242-554-01
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Genentech, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |